Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats

Abstract 1. This study was designed to evaluate how the absence of P-glycoprotein (Pgp, Mdr1a), breast cancer-resistance protein (Bcrp, Abcg2) or both affects drug distribution into sciatic nerves, brain and cerebrospinal fluid (CSF) in rats. 2. Pgp substrate (loperamide), BCRP substrates (dantrolene and proprietary compound X) and dual substrates (imatinib and proprietary compound Y) were well distributed into sciatic nerves with comparable nerve to plasma concentration ratios between wild-type and knockout (KO) rats. 3. Brain exposure increased substantially in Mdr1a(−/−) rats for loperamide and in Mdr1a(−/−)/Abcg2(−/−) rats for imatinib and compound Y, but minimally to modestly in Abcg2(−/−) rats for dantrolene and compound X. The deletion of Mdr1a or Abcg2 alone had little effect on brain distribution of compound Y. 4. While CSF to unbound brain concentration ratio remained ≥3 in the KO animals for dantrolene, compounds X and Y, it was reduced to 1 in the Mdr1a(−/−)/Abcg2(−/−) rats for imatinib. 5. The data indicate that Pgp and Bcrp do not play significant roles in drug distribution into peripheral nerve tissues in rats, while working in concert to regulate brain penetration. Our results further support that CSF concentration may not be a good surrogate for unbound brain concentration of efflux substrates.

[1]  Holger Fuchs,et al.  Brain Penetration of WEB 2086 (Apafant) and Dantrolene in Mdr1a (P-Glycoprotein) and Bcrp Knockout Rats , 2014, Drug Metabolism and Disposition.

[2]  S. Oka,et al.  Low Raltegravir Concentration in Cerebrospinal Fluid in Patients With ABCG2 Genetic Variants , 2014, Journal of acquired immune deficiency syndromes.

[3]  Xingrong Liu,et al.  Use of Cassette Dosing Approach to Examine the Effects of P-Glycoprotein on the Brain and Cerebrospinal Fluid Concentrations in Wild-Type and P-Glycoprotein Knockout Rats , 2014, Drug Metabolism and Disposition.

[4]  W. Elmquist,et al.  Pharmacokinetic Assessment of Efflux Transport in Sunitinib Distribution to the Brain , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[5]  K. Giacomini,et al.  Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. , 2013, Molecular pharmaceutics.

[6]  B. Wong,et al.  Deletion of Abcg2 Has Differential Effects on Excretion and Pharmacokinetics of Probe Substrates in Rats , 2012, Journal of Pharmacology and Experimental Therapeutics.

[7]  J. W. Higgins,et al.  Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics , 2012, Drug Metabolism and Disposition.

[8]  S. Vaidhyanathan,et al.  Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032) , 2012, Journal of Pharmacology and Experimental Therapeutics.

[9]  E. Sands,et al.  Cerebrospinal Fluid Can Be Used as a Surrogate to Assess Brain Exposures of Breast Cancer Resistance Protein and P-Glycoprotein Substrates , 2012, Drug Metabolism and Disposition.

[10]  C. Bundgaard,et al.  Species Comparison of In Vivo P-Glycoprotein-Mediated Brain Efflux Using mdr1a-Deficient Rats and Mice , 2012, Drug Metabolism and Disposition.

[11]  Zuo Zhang,et al.  Characterization of Multidrug Resistance 1a/P-Glycoprotein Knockout Rats Generated by Zinc Finger Nucleases , 2012, Molecular Pharmacology.

[12]  Yuichi Sugiyama,et al.  Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate , 2011, Journal of Pharmacology and Experimental Therapeutics.

[13]  R. Keep,et al.  Choroid plexus transport: gene deletion studies , 2011, Fluids and Barriers of the CNS.

[14]  T. Terasaki,et al.  Blood-Brain Barrier (BBB) Pharmacoproteomics: Reconstruction of In Vivo Brain Distribution of 11 P-Glycoprotein Substrates Based on the BBB Transporter Protein Concentration, In Vitro Intrinsic Transport Activity, and Unbound Fraction in Plasma and Brain in Mice , 2011, Journal of Pharmacology and Experimental Therapeutics.

[15]  Sagar Agarwal,et al.  Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux , 2010, Journal of Pharmacology and Experimental Therapeutics.

[16]  C. Waters,et al.  Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. , 2009, Cancer research.

[17]  F. Nelson,et al.  The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice , 2009, Drug Metabolism and Disposition.

[18]  Joseph W. Polli,et al.  An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.

[19]  J. Ghersi-Egea,et al.  Differential expression of the multidrug resistance‐related proteins ABCb1 and ABCc1 between blood‐brain interfaces , 2008, The Journal of comparative neurology.

[20]  Atsushi Ose,et al.  Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds , 2008, Drug Metabolism and Disposition.

[21]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[22]  P. Wielinga,et al.  Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy , 2004, Molecular and Cellular Biology.

[23]  T. Maurer,et al.  Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery , 2002, Biopharmaceutics & drug disposition.

[24]  D D Breimer,et al.  Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. , 2000, The Journal of clinical investigation.

[25]  Joseph W. Polli,et al.  Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor , 1999, Pharmaceutical Research.

[26]  A. Sartorelli,et al.  Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Roden,et al.  The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. , 1998, The Journal of clinical investigation.

[28]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[29]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[30]  S. Rapoport,et al.  Facilitated transport of L-phenylalanine across blood-nerve barrier of rat peripheral nerve. , 1990, The American journal of physiology.

[31]  L. Drewes,et al.  Glucose transporters at the blood-nerve barrier are associated with perineurial cells and endoneurial microvessels , 1990, Brain Research.

[32]  S. Rapoport,et al.  Structural Specificity of Sugar Transport at the Blood‐Nerve Barrier , 1989, Journal of neurochemistry.

[33]  S. Rapoport,et al.  Regulation of the microenvironment of peripheral nerve: Role of the blood-nerve barrier , 1987, Progress in Neurobiology.

[34]  K D Pettigrew,et al.  Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. , 1978, The American journal of physiology.

[35]  H. Davson.  Blood–brain barrier , 1977, Nature.

[36]  Ananda Weerasuriya,et al.  The blood-nerve barrier: structure and functional significance. , 2011, Methods in molecular biology.

[37]  Jiunn H. Lin,et al.  CSF as a surrogate for assessing CNS exposure: an industrial perspective. , 2008, Current drug metabolism.

[38]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.